CLINICAL TRIALS PROFILE FOR OMNARIS
✉ Email this page to a colleague
All Clinical Trials for omnaris
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00458835 ↗ | Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422) | Completed | AstraZeneca | Phase 4 | 2007-04-01 | The purpose of this study is to compare the systemic des-ciclesonide exposure of OMNARIS™ (ciclesonide) nasal spray, ciclesonide HFA nasal aerosol, and orally inhaled ciclesonide HFA-metered-dose inhaler (MDI). The administration of the study medication will be as follows: three single doses, separated by a wash-out period. The study will provide further data on the safety and tolerability of ciclesonide. |
| NCT01033825 ↗ | Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis | Completed | Sunovion | Phase 3 | 2010-01-01 | To demonstrate the effects of ciclesonide applied as a nasal aerosol and ciclesonide aqueous (AQ) nasal spray on hypothalamic-pituitary-adrenal axis. |
| NCT01430260 ↗ | Omnaris Versus Levocetirizine Phase 4 Study | Completed | Takeda | Phase 4 | 2011-01-01 | This i a comparison of the efficacy ciclesonide nasal spray and levocetirizine, alone and in combination. |
| NCT01430260 ↗ | Omnaris Versus Levocetirizine Phase 4 Study | Completed | Handok Inc. | Phase 4 | 2011-01-01 | This i a comparison of the efficacy ciclesonide nasal spray and levocetirizine, alone and in combination. |
| NCT01430260 ↗ | Omnaris Versus Levocetirizine Phase 4 Study | Completed | Handok Pharmaceuticals Co., Ltd. | Phase 4 | 2011-01-01 | This i a comparison of the efficacy ciclesonide nasal spray and levocetirizine, alone and in combination. |
| NCT01550471 ↗ | Sunovion Growth Study Pediatric Subjects With Mild Asthma & Allergic Rhinitis | Completed | West Penn Allegheny Health System | Phase 4 | 2012-03-01 | This study will provide the clinicians guidance on the safest combination of inhaled and nasal corticosteroids for children with mild asthma and allergic rhinitis respectively; however, one safety concern is that these products are independently known to have dose-related effects on short term and intermediate term growth. Knemometry is a non invasive technique for measuring short-term lower leg growth in children and is currently the method of choice in growth studies of short duration. Subjects will be seen on a weekly basis for 18 weeks and at each visit, lower leg length will be measured using knemometry. |
| NCT01654536 ↗ | A 6 Month Safety Study Of Ciclesonide Nasal Aerosol (Zetonna®) And Ciclesonide Nasal Spray (Omnaris®) In Subjects 12 Years And Older With Perennial Allergic Rhinitis (PAR) | Completed | Sunovion | Phase 4 | 2012-09-01 | This is a 6 month, multicenter, randomized, open label, parallel group, study to evaluate the nasal safety of ciclesonide nasal aerosol and ciclesonide aqueous nasal spray administered once daily to male and female subjects 12 years and older diagnosed with PAR. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for omnaris
Condition Name
Clinical Trial Locations for omnaris
Trials by Country
Clinical Trial Progress for omnaris
Clinical Trial Phase
Clinical Trial Sponsors for omnaris
Sponsor Name
